NEUP

2.3501.29%
DI

David Ian Wilson

Independent Non-Executive Director

Mr. David Ian Wilson serves as Founding Partner of WG Partners LLP and its Executive Chairman and Chief Executive Officer since November 2011. Mr. Wilson has experience in global investment banking with specialist knowledge in life sciences financing and M+A. Mr. Wilson served as the Senior Board Advisor of Sapia Partners LLP. Prior to WG Partners LLP, Mr. Wilson worked at Piper Jeffrey in various roles from 2001 to 2011. Previously, he served as the Chief Executive Officer of European Operations at Piper Jeffrey Limited since June 7, 2005. Mr. Wilson had ultimate responsibility for all of Piper Jaffray 's European institutional sales, trading and investment banking operations. He joined Piper Jeffrey in 2001 as head of European Investment Banking. He served as Head of U K Operations of Piper Jeffrey Companies. He was also on the Group Leadership Team and served as Chairman of Piper Jeffrey's Global Healthcare Group and a Member of the Global Operating Board. He served as Director of Investment Banking at Deutsche Bank AG (UK), and Head of Small Companies Corporate Broking at UBS. Prior to joining Piper Jeffrey, Mr. Wilson was also a Managing Director of ING Investment Banking from 1999 to 2001 and the Head of Small Companies Corporate Finance at Deutsche Bank from 1998 to 1999. He has spent years in the corporate finance area, founding the Small Company Investment Banking Team at BTAB/Deutsche Bank and working as head of Smaller Company Corporate Broking at UBS Warburg, which was ranked at the top in the Reuters and Extel surveys in the City of London. He also spent four years as an equity analyst at Lehman Brothers and Lombard Odier. He has been Independent Non-Executive Director at Neuphoria Therapeutics Inc. (formerly known as Bionomics Limited) since June 16, 2016. He also served as a Non?Executive Director of Optos plc since June 01, 2011 until May 22, 2015 and served as its Senior Independent Director until May 22, 2015. He served as a Director of BerGenBio AS from June 2013 to February 2016. He is on the board of directors of CS Pharmaceuticals Limited since July 2021. Mr. Wilson received his Bachelor?s degree from the University of Cambridge.

Positions